GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
BioSpace6d
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
GSK Shares Jump After Drugmaker Boosts Outlook, Positive Quarterly Results
American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...
in-cumbria.com6d
End of an era for pharmaceutical giant GSK
A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...
Seeking Alpha6d
GSK outlines 2025 growth driven by specialty medicines and new product launches
CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...
European markets open mixed ahead of more earnings reports; GSK up 6%
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
Yahoo Finance6d
GSK lifts long-term sales targets on new drug pipeline
Pharmaceuticals giant GlaxoSmithKline (GSK.L) (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an ...